Chinese pharma companies staged a major showcase of three fast-followers of AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s massively successful antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) during the American Association for Cancer Research (AACR) annual conference, touting the potential of three home-grown rivals to outdo the first-in-class drug in terms of efficacy and safety.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?